secwatch.observer — SEC 8-K summary
======================================

Issuer:     HALOZYME THERAPEUTICS, INC. (HALO)
CIK:        0001159036
Form:       8-K
Filed at:   2025-02-18T23:59:59+00:00
Accession:  0001159036-25-000008
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Halozyme reports record 2024 revenue of $1.015B, Q4 net income up 60% YoY
-------------------------------------------------------------------------

- Q4 total revenue $298M (+30% YoY); royalty revenue $170M (+40% YoY).
- Q4 GAAP EPS $1.06 (+63% YoY); non-GAAP EPS $1.26 (+54% YoY).
- Full-year 2024 total revenue $1,015M (+22% YoY); net income $444M (+58% YoY).
- Full-year adjusted EBITDA $632M (+48% YoY), exceeding guidance.
- Reiterates 2025 guidance: total revenue $1,150-1,225M, non-GAAP EPS $4.95-5.35.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1159036/000115903625000008/0001159036-25-000008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1159036/000115903625000008/halo-20250218.htm
  HTML page:      https://secwatch.observer/filing/0001159036-25-000008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer